UAlberta ACTM signs MOU to expand capacity for treatment, vaccine production

September 14, 2021
The University of Alberta’s Alberta Cell Therapy Manufacturing (ACTM) facility, The Ottawa Hospital’s Biotherapeutics Manufacturing Centre, and BioCanRx have signed a MOU that will expand Canada’s capacity for manufacturing vaccines, gene therapies, and cell therapies. The collaboration will provide vaccine makers, medical researchers, and pharmaceutical companies with the opportunity to have their products manufactured in Canada. “For Canada to play a key role in new breakthrough therapies and vaccines, we must invest in multiple facilities across the country and foster collaboration,” said ACTM scientific director Greg Korbutt. “This agreement sets the stage for a Canadian biomanufacturing ecosystem.” UAlberta (AB)